Degraded TPO agonist antibody
US8586039B2 · kind B2 · utility
19Cited by
20References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 6, 2011 |
| Grant date | Nov 19, 2013 |
| Priority date | — |
| Expiry date | Sep 6, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.